Literature DB >> 24119131

Mechanisms of hemolysis-associated platelet activation.

C C Helms1, M Marvel, W Zhao, M Stahle, R Vest, G J Kato, J S Lee, G Christ, M T Gladwin, R R Hantgan, D B Kim-Shapiro.   

Abstract

BACKGROUND: Intravascular hemolysis occurs after blood transfusion, in hemolytic anemias, and in other conditions, and is associated with hypercoagulable states. Hemolysis has been shown to potently activate platelets in vitro and in vivo, and several mechanisms have been suggested to account for this, including: (i) direct activation by hemoglobin (Hb); (ii) increase in reactive oxygen species (ROS); (iii) scavenging of nitric oxide (NO) by released Hb; and (iv) release of intraerythrocytic ADP.
OBJECTIVE: To elucidate the mechanism of hemolysis-mediated platelet activation.
METHODS: We used flow cytometry to detect PAC-1 binding to activated platelets for in vitro experiments, and a Siemens' Advia 120 hematology system to assess platelet aggregation by using platelet counts from in vivo experiments in a rodent model.
RESULTS: We found that Hb did not directly activate platelets. However, ADP bound to Hb could cause platelet activation. Furthermore, platelet activation caused by shearing of red blood cells (RBCs) was reduced in the presence of apyrase, which metabolizes ADP to AMP. The use of ROS scavengers did not affect platelet activation. We also found that cell-free Hb enhanced platelet activation by abrogating the inhibitory effect of NO on platelet activation. In vivo infusions of ADP and purified (ADP-free) Hb, as well as hemolysate, resulted in platelet aggregation, as shown by decreased platelet counts.
CONCLUSION: Two primary mechanisms account for RBC hemolysis-associated platelet activation: ADP release, which activates platelets; and cell-free Hb release, which enhances platelet activation by lowering NO bioavailability.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  hemoglobin; hemolysis; nitric oxide; platelets; red blood cells

Mesh:

Substances:

Year:  2013        PMID: 24119131      PMCID: PMC3947421          DOI: 10.1111/jth.12422

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  46 in total

1.  Kinetic and mechanistic studies of the NO*-mediated oxidation of oxymyoglobin and oxyhemoglobin.

Authors:  S Herold; M Exner; T Nauser
Journal:  Biochemistry       Date:  2001-03-20       Impact factor: 3.162

2.  Nitric oxide red blood cell membrane permeability at high and low oxygen tension.

Authors:  Kris T Huang; Zhi Huang; Daniel B Kim-Shapiro
Journal:  Nitric Oxide       Date:  2006-12-05       Impact factor: 4.427

Review 3.  Nitric oxide insufficiency, platelet activation, and arterial thrombosis.

Authors:  J Loscalzo
Journal:  Circ Res       Date:  2001-04-27       Impact factor: 17.367

4.  State of the art in platelet function testing.

Authors:  Beate E Kehrel; Martin F Brodde
Journal:  Transfus Med Hemother       Date:  2013-03-18       Impact factor: 3.747

5.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

6.  Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.

Authors:  C J Foster; D M Prosser; J M Agans; Y Zhai; M D Smith; J E Lachowicz; F L Zhang; E Gustafson; F J Monsma; M T Wiekowski; S J Abbondanzo; D N Cook; M L Bayne; S A Lira; M S Chintala
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

7.  The binding of phosphorylated red cell metabolites to human hemoglobin A.

Authors:  N Hamasaki; Z B Rose
Journal:  J Biol Chem       Date:  1974-12-25       Impact factor: 5.157

8.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

9.  Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C.

Authors:  D Praticó; M Pasin; O P Barry; A Ghiselli; G Sabatino; L Iuliano; G A FitzGerald; F Violi
Journal:  Circulation       Date:  1999-06-22       Impact factor: 29.690

10.  Divergent nitric oxide bioavailability in men and women with sickle cell disease.

Authors:  Mark T Gladwin; Alan N Schechter; Frederick P Ognibene; Wynona A Coles; Christopher D Reiter; William H Schenke; Gyorgy Csako; Myron A Waclawiw; Julio A Panza; Richard O Cannon
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

View more
  42 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

2.  Mechanistic insights into cell-free hemoglobin-induced injury during septic shock.

Authors:  Jeffrey Wang; Willard N Applefeld; Junfeng Sun; Steve B Solomon; Jing Feng; Zoe G Couse; Thomas F Risoleo; Robert L Danner; Jesús Tejero; Juan Lertora; Elmira Alipour; Swati Basu; Vandana Sachdev; Daniel B Kim-Shapiro; Mark T Gladwin; Harvey G Klein; Charles Natanson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-05-14       Impact factor: 4.733

Review 3.  Mechanisms of Hemolysis During Sepsis.

Authors:  Katharina Effenberger-Neidnicht; Matthias Hartmann
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

Review 4.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

5.  Routine clinical anti-platelet agents have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support.

Authors:  Lorenzo Valerio; Jawaad Sheriff; Phat L Tran; William Brengle; Alberto Redaelli; Gianfranco B Fiore; Federico Pappalardo; Danny Bluestein; Marvin J Slepian
Journal:  Thromb Res       Date:  2017-12-05       Impact factor: 3.944

6.  Compartmentalization Is Key in Limiting Nitric Oxide Scavenging by Cell-Free Hemoglobin.

Authors:  Daniel B Kim-Shapiro; Rakesh P Patel
Journal:  Am J Respir Crit Care Med       Date:  2016-05-15       Impact factor: 21.405

7.  Arginine for mitochondrial oxidative enzymopathy.

Authors:  Daniel B Kim-Shapiro; Mark T Gladwin
Journal:  Blood       Date:  2020-09-17       Impact factor: 22.113

8.  Microfludic platforms for the evaluation of anti-platelet agent efficacy under hyper-shear conditions associated with ventricular assist devices.

Authors:  Annalisa Dimasi; Marco Rasponi; Filippo Consolo; Gianfranco B Fiore; Danny Bluestein; Marvin J Slepian; Alberto Redaelli
Journal:  Med Eng Phys       Date:  2017-08-30       Impact factor: 2.242

9.  Investigation of the Etiology of Anemia in Thromboangiitis Obliterans.

Authors:  Mohammad Mehdi Akbarin; Hassan Ravari; Ataollah Rajabnejad; Narges Valizadeh; Bahare Fazeli
Journal:  Int J Angiol       Date:  2016-01-12

10.  Hemolysate-mediated platelet aggregation: an additional risk mechanism contributing to thrombosis of continuous flow ventricular assist devices.

Authors:  Phat L Tran; Maria-Grazia Pietropaolo; Lorenzo Valerio; William Brengle; Raymond K Wong; Toshinobu Kazui; Zain I Khalpey; Alberto Redaelli; Jawaad Sheriff; Danny Bluestein; Marvin J Slepian
Journal:  Perfusion       Date:  2015-11-20       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.